The presented data indicates that PARP1 inhibition through the use of AZD2461 has cytostatic capabilities comparable to those of imatinib treatment in ALL p190+ cell models, inhibiting neoplastic clone proliferation due to G0/G1 phase arrest. Here, PARP1 is linked to acute lymphoblastic leukemia.